EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, CytomX Therapeutics's Enterprise Value is $306.4 Mil.
CytomX Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2025 was $-81.5 Mil. Therefore, CytomX Therapeutics's EV-to-FCF for today is -3.76.
The historical rank and industry rank for CytomX Therapeutics's EV-to-FCF or its related term are showing as below:
CTMX'
s EV-to-FCF Range Over the Past 10 Years
Min: -110.8 Med: -0.06 Max: 43.45
Current: -3.76
During the past 12 years, the highest EV-to-FCF of CytomX Therapeutics was 43.45. The lowest was -110.80. And the median was -0.06.
CTMX's EV-to-FCF is ranked worse than 100% of 395
companies
in the Biotechnology industry
Industry Median: 7.51
vs CTMX: -3.76
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
The historical data trend for CytomX Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of CytomX Therapeutics's EV-to-FCF
For the Biotechnology subindustry, CytomX Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CytomX Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CytomX Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where CytomX Therapeutics's EV-to-FCF falls into.
CytomX Therapeutics's current Enterprise Value is $306.4 Mil.
CytomX Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-81.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
CytomX Therapeutics's PE Ratio (TTM) for today is calculated as:
CytomX Therapeutics's share price for today is $2.49.
CytomX Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.490.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
CytomX Therapeutics EV-to-FCF Related Terms
Thank you for viewing the detailed overview of CytomX Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CTMX has been successfully added to your 